Valuation: Tonix Pharmaceuticals Holding Corp

Market Cap 191M 168M 155M 145M 271M 18.02B 276M 1.85B 718M 8.88B 717M 701M 30.87B P/E 2026 *
-1.17x
P/E 2027 * -1.93x
Enterprise Value 191M 168M 155M 145M 271M 18.02B 276M 1.85B 718M 8.88B 717M 701M 30.87B EV / Sales 2026 *
5.59x
EV / Sales 2027 * 2.42x
Free-Float
99.87%
Yield 2026 *
-
Yield 2027 * -
06-08 Tonix Pharmaceuticals Enters Second Commercial Payer Deal, Expands Drug Coverage MT
06-08 Tonix Pharmaceuticals Holding Corp. Enters Agreement With Group Purchasing Organization For Commercial Coverage Of TONMYA CI
05-29 Tonix Pharmaceuticals Holding Corp. Presents Data from Real-World Claims Analysis of Opioid Use in U.S. Adults with Fibromyalgia at 2026 ASCP Annual Meeting CI
05-27 Tonix Pharmaceuticals Holding Corp. Announces Publication Of Phase 1 Clinical Data Of TNX-1500 Fc-Modified Anti-CD40L Monoclonal Antibody CI
05-26 Tonix Pharmaceuticals Presents Real-World Claims Analysis And Launches TONMYA For Fibromyalgia Treatment CI
05-12 Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-06 Tonix Pharmaceuticals Holding Corp. Secures Commercial Payer Coverage for TONMYA CI
05-04 U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower RE
05-04 TD Cowen Initiates Coverage on Tonix Pharmaceuticals With Buy Rating, $22 Price Target MT
04-29 Tonix Pharmaceuticals Holding Corp. Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of Tnx-4800 CI
03-31 Tonix Pharmaceuticals Holding Corp Presents Phase 1 Data And Outlines Planned Adaptive Phase 2 Field Study Of TNX-4800 For Prevention Of Lyme Disease CI
03-26 Tonix Pharmaceuticals Doses First Participant in Potential Migraine Treatment Study MT
03-26 Tonix Pharmaceuticals Holding Corp Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 CI

Last Transcript: Tonix Pharmaceuticals Holding Corp

Manager TitleAgeSince
Chief Executive Officer 68 16/11/2007
Director of Finance/CFO 52 01/02/2016
Chief Tech/Sci/R&D Officer 57 04/02/2025
Director TitleAgeSince
Chairman 68 01/10/2011
Director/Board Member 66 12/09/2017
Director/Board Member 81 05/09/2018
Change 5-day change 1-year change 3-year change Capi.($)
+0.93%+2.65%+42.33%+145.77% 996B
+1.61%+7.22%+60.81%+47.98% 580B
+3.51%+12.31%+31.15%+78.88% 415B
+0.99%+5.11%+29.26%+21.27% 326B
+1.09%+6.90%+37.22%+23.11% 284B
+1.34%+6.74%+32.63%+38.93% 280B
+1.32%+12.69%-27.48%-42.00% 210B
+0.40%+4.51%+25.85%+55.35% 190B
-1.05%+0.06%+16.91%+59.86% 155B
Average +1.13%+5.12%+27.63%+47.68% 381.86B
Weighted average by Cap. +1.31%+4.81%+35.33%+70.19%

Financials

2026 *2027 *
Net sales 34.18M 30.03M 27.67M 25.87M 48.52M 3.23B 49.41M 332M 129M 1.59B 128M 126M 5.53B 78.93M 69.34M 63.88M 59.73M 112M 7.45B 114M 766M 297M 3.67B 296M 290M 12.76B
Net income -170M -149M -138M -129M -241M -16.04B -246M -1.65B -639M -7.91B -638M -624M -27.47B -152M -133M -123M -115M -215M -14.33B -219M -1.47B -571M -7.06B -570M -558M -24.54B
Net Debt - -
Logo Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-